News Release

Scientists determine how microbes make drug-like chemicals without damaging themselves

Peer-Reviewed Publication

University of Michigan

ANN ARBOR—University of Michigan researchers have discovered a mechanism that enables microscopic organisms like bacteria and fungi to produce drug-like molecules—compounds that can fight infections or kill cancer cells—without damaging themselves.

This cellular mechanism is driven by a protein that simultaneously strengthens the chemical reactions that generate these important molecules while shielding the organism from harmful by-products of those reactions.

The study, published in Science, opens new avenues to discovering novel chemical compounds produced in nature and to improving the pharmaceutical properties of existing natural product therapeutics.

Paradox in one anticancer compound uncovers tens of thousands of protective proteins

The discovery emerged when researchers in the lab of David Sherman at the U-M Life Sciences Institute were investigating how Streptomyces bacteria make doxorubicin, a widely used anticancer drug.

The final step in the bacterial manufacturing process requires an enzyme called CYP450 to convert the starting compound into doxorubicin. While trying to coax the bacteria into more efficient production of doxorubicin, the team noticed that the conditions required for the CYP450 to work were also causing the doxorubicin anticancer therapeutic molecule to degrade.

"We saw this paradox that the organism that produces this anticancer drug is doing so under conditions that can also lead to destruction of the drug," said Sherman, a faculty member at the Life Sciences Institute and senior author of the new study. "And so we knew there must be something really interesting happening in the natural system that allowed the bacteria to overcome this paradox."

The team analyzed the gene cluster in Streptomyces that is responsible for making doxorubicin and discovered that a gene called DnrV, which sits directly next to the CYP450 gene, was essential for preserving the drug molecule. But beyond that, the DnrV protein was protecting the bacteria and even improving the chemical reaction toward maximizing doxorubicin production.

These chemical reactions driven by CYP450 produce reactive oxygen species as byproducts. These highly unstable ROS molecules can cause genetic mutations and harm cellular function.

"We were able to demonstrate that DnrV has this multifunctional role, where it protects the organism against ROS. But the most surprising aspect is its third function, which is that this protein was actually enhancing the function of the CYP450 enzyme, leading to a more efficient reaction," said Sherman, who is also a professor of medicinal chemistry at the College of Pharmacy, professor of microbiology and immunology at the Medical School, and professor of chemistry at the College of Literature, Science, and the Arts.   

Through additional bioinformatic and genetic analyses, Sherman and colleagues also uncovered a large family of more than 40,000 proteins that perform similar functions across plants, bacteria and fungi. The researchers have dubbed this family REACT (short for REdox-Associated CytoToxin binding) proteins. 

"It felt a bit like unraveling a ball of yarn," said Hannah Boesger, a graduate student in the Sherman lab and first author of the study.  "Our efforts to overcome this one doxorubicin paradox led to the discovery of this huge family of REACT proteins that protect both the microorganisms and the molecules they are creating."

REACT proteins offer tools for discovering, building novel pharmaceuticals

Approximately half of all pharmaceuticals on the market today have their origins in chemical products manufactured naturally by microscopic organisms such as bacteria and fungi. With the discovery of REACT proteins' role in building drug-like compounds, the team believes these proteins can now be used as a genetic marker for broadening this field, flagging biologically important natural products that have not yet been discovered.

"It can really help us get more targeted entry into uncovering important new structures with bioactivity," Sherman said. "Now we can begin to mine the genomes of other organisms for gene clusters that contain a REACT protein, indicating that they are likely to be producing compounds with anticancer or antimicrobial activities." 

 The REACT proteins could also serve as tools for building natural products more efficiently or building novel compounds with new pharmaceutical properties.

"P450 enzymes enable reactions that traditional chemical approaches cannot readily perform, and REACT proteins appear to enhance P450 activity," said Sean Newmister, a research scientist in Sherman's lab and a senior author of the study. "So, going forward, I can see many opportunities to explore new reactivities of P450s by pairing them with these REACT proteins in new engineered systems." 

In addition to Sherman, Boesger and Newmister, study authors include: Emma Fang, Ralph Harte and Areeba Momin of U-M; Rongbin Wang, Arina Koroleva and Mikko Metsä-Ketelä of the University of Turku, Finland; and Taylan Tunckanat and Sean Elliott of Boston University.

Research reported in this article was supported by the National Institutes of Health (grants R35GM118101, R35GM136294 and T32GM140223; the Novo Nordisk Foundation (grant NNF19OC0057511); the Academy of Finland Grants (grants 340013 and 354998); and the U.S. Department of Energy (grant DE-SC0012598). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.